Mr TAYLOR (Hume—Minister for Industry, Energy and Emissions Reduction) (14:12): I thank the Prime Minister for offering me the opportunity to add to his answer. Of course, an Australian manufacturer has already delivered 25 million vaccines, and there's potential to manufacture many more. This is all about making sure we have control over our own destiny, and that's why, on top of those 25 million vaccines that have been manufactured in this country, we're also developing a pathway to develop our own onshore manufacturing capability for mRNA. That has two core benefits. First of all, of course, it insures us against future pandemics and, indeed, variants such as we're seeing now. Also, it builds an industry capability and the jobs opportunity that comes with that. We know we are well positioned to build capacity in this very high-potential area of science. To get the best deal for Australia, we— The SPEAKER: The minister will resume his seat. The member for Chifley. Mr Husic: Mr Speaker, with respect, we don't need the background. My point of order is on direct relevance. When is it happening? That is what I asked. The SPEAKER: The member for Chifley will resume his seat. The minister has the call. The minister is being relevant. Mr TAYLOR: Thank you, Mr Speaker. As I was saying, we're taking a two-part approach. We're having discussions with Moderna, who manufacture one of only two approved mRNA products in the world. I've personally spoken with the head of Moderna in Australia and the chief executive globally. Secondly, we approached the market for proposals from industry and are asking what support they would need from government. We're working through that process thoroughly now. This is important for Australia, it's important for manufacturing and it's an important part of ensuring that we can control our own destiny. We're getting on with the job.